MetaCap

Bolt Biotherapeutics (BOLT) vs BeyondSpring (BYSI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BeyondSpring is the larger company by market cap ($13.7 million vs $12.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLT+36.39%BYSI-48.80%
+90%+17%-55%
Oct 7, 20261 yearNov 20, 2026
BOLT+19.46%BYSI-45.51%
+66%+7%-51%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLT versus BYSI key metrics
MetricBOLTBYSI
Share price$4.91$0.33
Market cap$12.80M$13.66M
1-day change-2.96%-24.49%
YTD return—-79.75%
1-year return—-82.77%
5-year return—-97.70%
EPS (TTM)$-14.00$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.70M$0
Revenue growth (YoY)+0.07%—
Net income (latest FY)$-33.38M$-1.01M
Operating margin-469.30%—
Net margin-433.74%—
52-week high$7.78$2.44
52-week low$3.10$0.299
Distance from 52-week high-36.89%-86.48%
Analyst consensusnone—
Avg. price target upside+490.63%—
Average volume257.43K261.79K
Shares outstanding2.61M41.41M
Employees2344
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bolt Biotherapeutics

BOLT stock →

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About BeyondSpring

BYSI stock →

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

BOLT vs BYSI FAQ

Which is bigger, Bolt Biotherapeutics or BeyondSpring?

BeyondSpring (BYSI) is larger, with a market capitalization of $13.66M compared with $12.80M for Bolt Biotherapeutics (BOLT).

Are Bolt Biotherapeutics and BeyondSpring in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons